Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis

IDrugs

Volumn 13, Issue 5, 2010, Pages 332-345

  Antoniu, Sabina A ^a   Kolb, Martin Rj ^b  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; FIBROBLAST GROWTH FACTOR RECEPTOR; INTEDANIB; PACLITAXEL; PEMETREXED; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG WITHDRAWAL; ESOPHAGUS PAIN; FATIGUE; FIBROSING ALVEOLITIS; GYNECOLOGIC CANCER; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PATENT; PROSTATE CANCER; REVIEW; SIDE EFFECT; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 77953195426     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Tumor angiogenesis: Therapeutic implications. Folkman J N Engl J Med 1971 285 21 1182-1186
2. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E et al Cancer Res 2000 60 8 2178-2189
3. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Hanks SA, Quinn AM, Hunter T Science1988. 241,42-52
4. FDA approves Avastin, a targeted therapy for first-line metastatic colorectal cancer patients. Genentech Inc Press Release2004 February 26
5. EORTC-NCI-AACR - 16th Symposium (Part II) - OVERNIGHT REPORT, Molecular Targets and Cancer Therapeutics, Geneva, Switzerland. Lunec A IDDB MEETINGREPORT 2004 September 28 - October 1
6. A clinical phase I dose escalation, pharmacokinetic (PK) and pharmacodynamic (PD) study of BIBF 1120 in advanced cancer patients. Mross K, Baas F, Medinger M, Drevs J, Stecker R, Hennig J, Wolters M, Stehle G, Stefanic M EJC Suppl 2004 2 8 Abs 135
7. A clinical phase I, pharmacokinetic (PK), and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients. Mross KB, Gmehling D, Frost A, Baas F, Strecker R, Hennig J, Stopfer P, Stefanic M, Stehle G, de Rossi L J CLIN ONCOL2005 23 16 Suppl Abs 3031
8. A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies. Lee CP, Attard G, Poupard L, Nathan PD, de Bono JS, Temple GM, Stefanic MF, Padhani AR, Judson IR, Rustin GJ J CLIN ONCOL2005 23 16 Suppl Abs 3054
9. In vitro and in vivo efficacy of BIBF 1120, a small molecule triple angiokinase inhibitor. Hilberg F, Brandsetter I, Roth GJ ClinCancer Res 2005 11 23 Suppl Abs A19
10. BIBF 1120, a small molecule triple angiokinase inhibitor, affects the tumor vasculature in human tumor xenografts on nude mice as detected by DCE-MRI. Krssk M, Kriz M, Stefanic M, Hilberg F ClinCancer Res 2005 11 23 Suppl Abs A22
11. Safety, pharmakokinetics and pharmacodynamics (DCE-MRI) in patients with metastatic colorectal cancer treated in a phase I study with BIBF 1120, the first triple angiokinase inhibitor. Mross K, Strecker R, Frost A, Unger C, Hennig J, Stefanic M, Stopfer P, Deichsel G, Stehle G, de Rossi L ClinCancer Res 2005 11 23 Suppl Abs A1
12. Pharmacokinetics of an oral VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584) in patients with myelodysplastic syndrome (MDS): Cancer and Leukemia Group B Study 10105. Gupta P, Miller AA, Owzar K, Murry DJ, Sanford BL, Vij R, Yu D, Hasserjian RP, Larson RA, Ratain MJ J CLIN ONCOL2006 24 18 Suppl Abs 6573
13. A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Lee CP, Taylor NJ, Attard G, Nathan PD, De Bono JS, Temple G, Tang A, Padhani AR, Judson IR, Rustin GJ J ClinOncol 2006 24 18 Suppl Abs 3015
14. FDA approves Avastin in combination with chemotherapy for first-line treatment of most common type of lung cancer. Genentech Inc Press Release2006 October 11
15. Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. Kulimova E, Oelmann E, Bisping G, Bisping J, Mesters RM, Schwable J, Hilberg F, Roth GJ, Munzert G, Stefanic M, Steffen B et al Mol Cancer Ther 2006 5 12 3105-3112
16. A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: Safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings. Jonker DJ, Rosen LS, Sawyer M, Wilding G, Noberasco C, Jayson G, Rustin G, McArthur G, Velasquez L, Galbraith S J ClinOncol 2007 25 18 Suppl Abs 3559
17. A phase I dose escalation and pharmacokinetic study of BIBF 1120 in combination with paclitaxel and carboplatin in patients with advanced gynecological malignancies. Harter P, Huober J, Pfisterer J, Wimberger P, Loibl S, Stopfer P, Kaiser R, Reichardt V, du Bois A J CLIN ONCOL2007 25 18 Suppl Abs 3561
18. A double blind phase II study of BIBF 1,120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC). Von Pawel J, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Reck M J CLIN ONCOL2007 25 18 Suppl Abs 7635
19. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Chaudhary NI, Roth GJ, Hilberg F, Muller-Ouernheim J, Prasse A, Zissel G, Schnapp A, Park JE EURRESPIRJ 2007 29 5 976-985
20. Avastin approved in Europe for first line treatment of women with metastatic breast cancer. Roche Holding AG Press Release2007 March 29
21. Industry's highest growth rate recorded twice in 2 years: NBI. Pharma Jpn2007 2037 April 16 3
22. NCT00514683: Safety and efficacy of BIBF 1120 in idiopathic pulmonary fibrosis. Boehringer Ingelheim Pharmaceuticals clinicaltrials.gov 2007 August 10
23. AstraZeneca provides update on RECENTINTM clinical development programme. AstraZeneca plc PRESSRELEASE 2008 February 27
24. Boehringer Ingelheim annual press conference 2008. Boehringer Ingelheim Corp Company Presentation2008 April 08
25. Data suggests promising overall survival and progression-free survival with Vargatef (BIBF 1120). Boehringer Ingelheim Corp Press Release2008 April 28
26. A phase II trial of PTK-787 (PTK/ZK) in recurrent or progressive meningiomas. DeBoer R, Grimm SA, Chandler J, Gallot L, Kennedy S, Burns K, Rice L, Cabreza C, Muro K, Raizer JJ J CLIN ONCOL2008 26 15 Suppl Abs 2060
27. Pharmacokinetic (PK) analysis of a phase I study of continuous oral treatment with the angiokinase inhibitor BIBF 1120, in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). Camidge DR, Conkling P, Stephenson JJ, Glassman PM, Zhao Y, Kaiser R, Stopfer P J CLIN ONCOL2008 26 15 Suppl Abs 3567
28. Cediranib (AZD-2171) for the treatment of recurrent small cell lung cancer (SCLC): A California Consortium phase II study (NCI # 7097). Ramalingam SS, Mack PC, Vokes EE, Longmate J, Govindan R, Koczywas M, Ivy SP, Belani CP, Gandara DR J CLIN ONCOL2008 26 15 Suppl Abs 8078
29. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J et al Cancer Res 2008, 68,12,4774-4782
30. A phase II trial of weekly alternating sequential administration of BIBF1120 and BIBW2992 in patients with advanced colorectal cancer. Bouche O, Ducreux M, Lledo G, Andre T, Maindrault-Goebel F, Stopfer P, Oum'Hamed Z, Chadjaa M, de Gramont A J CLIN ONCOL2008 26 15 Suppl Abs 15001
31. NCT00706628: A multi-centre 3-arm randomised phase II trial of BIBF 1120 versus BIBW-2992 versus sequential administration of BIBF 1120 and BIBW-2992 in patients with hormone-resistant prostate cancer. Boehringer Ingelheim Pharmaceuticals clinicaltrials.gov 2006
32. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Gschwind A, Fischer OM, Ullrich A NatRev Cancer2004, 4, 5,361-370
33. First pivotal trials begin for Boehringer Ingelheim's novel triple angiokinase inhibitor vargatef (BIBF 1120). Boehringer Ingelheim Corp Press Release2008 November 17
34. Amgen, Takeda and Millennium provide update on phase 3 trial of motesanib in patients with non-small cell lung cancer. Amgen Inc; Takeda Pharmaceutical Co Ltd PRESSRELEASE 2008 November 19
35. Pharmacokinetics of BIBF 1120 after administration of single doses of 100 mg [14C]-BIBF 1120. Stopfer P, Rathgen K, Liesener A, Gaschler-Markefski B, Kaiser R ANN ONCOL2008 19 Suppl,8,158-159
36. Pfizer discontinues global phase III trial of axitinib for futility in advanced pancreatic cancer. Pfizer Inc PRESSRELEASE 2009 January 30
37. Antitumor activity of a novel angiogenesis inhibitor BIBF1120 for hepatocellular carcinoma and a new pharamacodynamic biomarker in blood samples. Kudo K, Arao T, Tanaka K, Kaneda H, Maegawa M, Matsumoto K, Tamura D, Aomatsu K, Fujita Y, Kudo M, Nishio K AM ASSOC CANCERRESANN MEET,2009 100 April 19 Abs 148
38. A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). Ledermann JA, Rustin GJ, Hackshaw A, Kaye SB, Jayson G, Gabra H, James LE, Bell S, Temple G J CLIN ONCOL2009 27 15 Suppl Abs 5501
39. Phase I clinical and biomarker study of BIBF 1120, an oral multitarget tyrosine kinase inhibitor, in patients with advanced solid tumors (ST): Impact of CD133- and CD117-positive cells on a biomarker of an antiangiogenic inhibitor. Okamoto I, Kaneda H, Satoh T, Okamoto W, Terashima M, Arao T, Nishio K, Nakagawa K, Konishi K, Kaiser R J CLIN ONCOL2009 27 15 Suppl Abs 3572
40. An open-label phase II study of first and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). Raoul JL, Finn RS, Kang YK, Park JW, Harris R, Coric V, Donica M, Walters I J CLIN ONCOL2009 27 15 Suppl Abs 4577
41. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific. Roth GJ, Heckel A, Colbatzky F, Handschuh S, Kley J, Lehmann-Lintz T, Lotz R, Tontsch-Grunt U, Walter R, Hilberg F J Med Chem2009 52 14 4466-4480
42. NCT00806819: Lume lung 2: BIBF 1120 plus pemetrexed compared to placebo plus pemetrexed in 2nd line nonsquamous NSCLC. Boehringer Ingelheim Pharmaceuticals clinicaltrials.gov 2009
43. European Commission approves broader label for Avastin allowing combination with docetaxel for the first-linetreatment of advanced (metastatic) breast cancer. Roche Holding AG Press Release2009 July 29
44. Cooperative activities of the triple kinase inhibitor BIBF 1120 ant the irreversible EGFR/HER2 inhibitor BIBW 2992 in colorectal cancer models. Larsen A, Poindessous V, Kamsu-Kom N, Ouaret D, Escargueil A, el Ouadrani K, Dartigues P, Dumont S, Solca F, Hilberg F, Stahle G, de Gramont A ANN ONCOL2009 20 Suppl 7 30
45. A phase II double-blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small cell lung cancer. Reck M, Kaiser R, Eschbach C, Stefanie M, Love J, Staab A, Freiwald M, Bruno R, Stopfer P, Gatzemeier U, von Pawel J J ThoracicOncol 2009 4 9 Suppl 1 Abs P1.236
46. FDA approves new treatment for advanced form of kidney cancer. The Food and Drug Administration Press Release2009 October 19
47. Astrazeneca withdraws regulatory submissions for Zactima (vandetanib) in combination with chemotherapy for advanced NSCLC. AstraZeneca plc PRESSRELEASE 2009 October 28
48. An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma. Kropff M, Kienast J, Bisping G, Berdel WE, Gaschler-Markefski B, Stopfer P, Stefanic M, Munzert G Anticancer Res 2009 29 10 4233-4238
49. Antitumor activity of a novel angiogenesis inhibitor BIBF 1120 for hepatocellular carcinoma and a new pharmacodynamic biomarker in blood samples. Kudo M, Kudo K, Arao T, Nishio K HEPATOLOGY2009 50 Suppl 4 1099A
50. Boehringer Ingelheim initiates first phase III clinical trial in ovarian cancer. Boehringer Ingelheim Corp Press Release2009 December 17
51. Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumors. Kaneda H, Okamoto I, Satoh T, Arao T, Nishio K, Sarashina A, Konishi K, Stopfer P, Kaiser R, Nakagawa K EJC Suppl 2009 7 2 133
52. Pharmacokinetic (PK) analysis of two dosing schedules of the angiokinase inhibitor BIBF 1120 in patients with hormone- refractory prostate cancer (HRPC) who progressed after docetaxel treatment. Droz JP, Flechon A, Joly F, de Mont-Serrat H, Kaiser R, Stopfer P, Oudard S J CLIN ONCOL2008 26 15 Suppl Abs 14578
53. AstraZeneca development pipeline, 28 January 2010. AstraZeneca plc COMPANYWORLDWIDE WEB SITE 2010 January 28
54. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt VL, Harter P AnnOncol 2010 21 2 370-375
55. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Mross K, Stefanic M, Gmehling D, Frost A, Baas F, Unger C, Strecker R, Henning J, Gaschler-Markefski B, Stopfer P, De Rossi L et al ClinCancer Res 2010,16, 1,311-319
56. Quantitative mapping of hepatic perfusion index using MR imaging: A potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. Miyazaki K, Collins DJ, Walker-Samuel S, Taylor JN, Padhani AR, Leach MO, Koh DM Eur Radiol 2008 18 7 1414-1421
57. Targeting the endothelin pathway in the idiopathic pulmonary fibrosis: The role of bosentan. Antoniu SA EXPERT OPIN THERTARGETS2008 12 9 1077-1084
58. Anti-angiogenic tyrosine kinase inhibitors: What is their mechanism of action? Gotink KJ, Verheul HM Angiogenesis 2010 13 1 1-14
59. Tumor angiogenesis. Kerbel RS N Engl J Med 2008 358 19 2039-2049
60. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, Ferrara N NatBiotechnol 2007 25 8 911-920
61. Antiangiogenic agents and vascular disrupting agents for the treatment of lung cancer: A review. Clement-Duchene C, Wakelee H J ThoracOncol 2010 5 1 129-139
62. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Casanovas O, Hicklin DJ, Bergers G, Hanahan D Cancer Cell 2005 8 4 299-309
63. A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC). Stopfer P, Freiwald M, Liesenfeld KH, Bruno R, Hodge L, Eschbach C, Reck M, von Pawel J, Kaiser R, Staab A EJC SUPPL2009 7 2 551
64. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. Farkas L, Farkas D, Ask K, Moller A, Gauldie J, Margetts P,Inman M, Kolb M J ClinInvest2009 119 5 1298-1311
65. Pharmacokinetic (PK) analysis of a phase I trial investigating continuous treatment with the angiokinase inhibitor BIBF 1120 combined with pemetrexed in previously treated patients with non-small cell lung cancer (NSCLC). Hanna NH, Zhao Y, Kaiser R, Stopfer P, Gyorffy S Ellis PM J CLIN ONCOL2008 26 15 Suppl Abs 14511
66. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Bhide RS, Lombardo LJ, Hunt JT, Cai Z-W, Barrish JC, Galbraith S, Jeyaseelan Sr R, Mortillo S, Wautlet BS, Krishnan B, Kukral D et al Mol Cancer Ther 2010 9 2 369-378
67. Angiogenesis inhibition in cancer therapy: Platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: Biological functions and role in malignancy. Appelmann I, Liersch R, Kessler T, Mesters RM, Berdel WE RECENT RESULTSCANCERRES2010 180 51-81
68. Fibroblast growth factor signalling: From development to cancer. Turner N, Grose R NatRev Cancer 2010 10 116-129
69. Sunitinib. Heng DY, Kollmannsberger C RECENT RESULTSCANCERRES2010 184 71-82
70. Sorafenib. Hasskarl J RECENT RESULTSCANCERRES2010 184 61-70
71. Efficacy of BIBF 1120, a potent triple angiokinase inhibitor, in models of human non-small cell lung cancer is augmented by chemotherapy. Hilberg F, Brandstetter I J THORACIC ONCOL2007 2 8 S380
72. An open label randomized phase ii study of oral triple angiokinase inhibitor BIBF 1120 in hormone refractory prostate cancer (HRPC) patients who progressed after docetaxel. Oudard S, Chevreau C, Flechon A, Gunzer K, Houede N, Krakowski I, de Mont-Serrat H, Rouyrre N, Kaiser R, Droz JP EJC SUPPL2007 5 4 280
73. Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas. Zips D, Le K, Yaromina A, Dorfler A, Eicheler W, Zhou XJ, Geyer P, Hilberg F, Baumann M RADIOTHERONCOL2009 92 3 405-410
74. NCT01004003: Phase I/II comparison of efficacy and safety of BIBF 1120 and sorafenib in patients with advanced hepatocellular carcinoma. Boehringer Ingelheim Corp CLINICALTRIALS.GOV2009
75. NCT01024920: Compare safety and efficacy of BIBF 1120 versus sunitinib. Boehringer Ingelheim Corp CLINICALTRIALS.GOV2009